Temozolomide gel - Double Bond Pharmaceutical/RUE Belmedpreparaty

Drug Profile

Temozolomide gel - Double Bond Pharmaceutical/RUE Belmedpreparaty

Alternative Names: SI 053; Temodex

Latest Information Update: 04 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Research Institute for Physical Chemical Problems of the Belarusian State University
  • Developer Double Bond Pharmaceutical; RUE Belmedpreparaty
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioblastoma

Most Recent Events

  • 04 Jun 2018 Chemical structure information added
  • 04 May 2018 Double Bond Pharmaceutical plans a phase I dose-escalation trial for Glioblastoma in European Union in 2018 (Double Bond Pharmaceutical website, April 2018)
  • 18 Apr 2018 Efficacy data from a phase II trial in Glioblastoma released by Double Bond Pharmaceutical (Double Bond Pharmaceutical website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top